Published in J Virol on November 17, 2010
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog (2014) 1.88
Animal models for HIV/AIDS research. Nat Rev Microbiol (2012) 1.71
Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog (2012) 1.26
Nonhuman primate models in AIDS research. Curr Opin HIV AIDS (2013) 1.18
Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies. Curr Opin HIV AIDS (2013) 1.10
Persistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant. PLoS Pathog (2014) 1.01
Exposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaques. PLoS One (2014) 0.92
Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model. PLoS One (2013) 0.92
Nonhuman primate models for HIV cure research. PLoS Pathog (2012) 0.90
Amplifying and quantifying HIV-1 RNA in HIV infected individuals with viral loads below the limit of detection by standard clinical assays. J Vis Exp (2011) 0.86
Effect of combination antiretroviral therapy on Chinese rhesus macaques of simian immunodeficiency virus infection. AIDS Res Hum Retroviruses (2013) 0.86
Controversies in HIV cure research. J Int AIDS Soc (2012) 0.84
Animal Models for HIV Cure Research. Front Immunol (2016) 0.80
Well-mixed plasma and tissue viral populations in RT-SHIV-infected macaques implies a lack of viral replication in the tissues during antiretroviral therapy. Retrovirology (2015) 0.78
PAPNC, a novel method to calculate nucleotide diversity from large scale next generation sequencing data. J Virol Methods (2014) 0.78
Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics. Antimicrob Agents Chemother (2014) 0.78
Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV. PLoS One (2014) 0.77
Viral latency and potential eradication of HIV-1. Expert Rev Anti Infect Ther (2012) 0.77
Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase. Antimicrob Agents Chemother (2015) 0.77
Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution. PLoS One (2014) 0.77
Identification of the peptide-binding motif recognized by the pigtail macaque class I MHC molecule Mane-A1*082:01 (Mane A*0301). Immunogenetics (2012) 0.76
Stable HIV-1 integrase diversity during initial HIV-1 RNA decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy. Virol J (2013) 0.75
Genetic variation and geographic differentiation among populations of the nonmigratory agricultural pest Oedaleus infernalis (Orthoptera: Acridoidea) in China. J Insect Sci (2015) 0.75
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science (1995) 18.40
A statistical test for detecting geographic subdivision. Mol Biol Evol (1992) 8.79
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med (2004) 6.29
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis (2008) 4.86
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis (2010) 2.51
Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS (1999) 2.00
Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol (2008) 1.91
A robust measure of HIV-1 population turnover within chronically infected individuals. Mol Biol Evol (2004) 1.87
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis (1995) 1.79
Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol (1998) 1.75
Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS (2004) 1.65
Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis (2004) 1.34
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol (2007) 1.30
The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr (2000) 1.29
CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses (2004) 1.26
Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis (2006) 1.26
Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology (1999) 1.23
HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr (2005) 1.23
Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med (2006) 1.21
Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.21
Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis (2005) 1.20
Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS (2002) 1.04
Issues in combination antiretroviral therapy: a review. J Acquir Immune Defic Syndr (1994) 0.98
Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. Top HIV Med (2005) 0.97
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob Agents Chemother (1994) 0.95
Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J Virol (1993) 0.94
Lymphoid tissue viral burden and duration of viral suppression in plasma. AIDS (2001) 0.92
Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis (1994) 0.92
Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. PLoS One (2010) 0.83
Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, India. AIDS Res Hum Retroviruses (2005) 0.82
Studies of zidovudine in combination with didanosine and zalcitabine. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.81
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: monotherapy. Hosp Pract (Off Ed) (1992) 0.79
Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. Scand J Infect Dis (2005) 0.79
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol (2005) 7.91
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 7.33
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol (2004) 6.26
Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science (2003) 6.22
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol (2005) 5.76
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Glycerol monolaurate prevents mucosal SIV transmission. Nature (2009) 5.02
Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest (2005) 5.00
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 4.41
The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol (2006) 4.26
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med (2009) 4.22
Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med (2007) 4.14
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95
Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol (2006) 3.80
Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One (2012) 3.69
Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med (2004) 3.62
Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol (2007) 3.61
Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol (2007) 3.59
Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol (2006) 3.59
Recombinant origin of the retrovirus XMRV. Science (2011) 3.54
Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med (2007) 3.45
Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood (2003) 3.40
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 3.27
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. AIDS (2002) 3.19
Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature (2013) 3.14
Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol (2004) 3.12
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe (2010) 3.08
Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis (2006) 3.04
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A (2003) 3.02
Patients with new onset haematuria: assessing the discriminant value of clinical information in relation to urological malignancies. Br J Gen Pract (2002) 3.01
The solitary wave of asexual evolution. Proc Natl Acad Sci U S A (2003) 2.97
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Effects of retroviruses on host genome function. Annu Rev Genet (2008) 2.96
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
Endogenous non-retroviral RNA virus elements in mammalian genomes. Nature (2010) 2.91
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One (2007) 2.84
Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology (2010) 2.75
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood (2013) 2.72
HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72
Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS (2006) 2.71
Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr (2002) 2.70
HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog (2011) 2.68
Mouse DNA contamination in human tissue tested for XMRV. Retrovirology (2010) 2.65
Symmetrical base preferences surrounding HIV-1, avian sarcoma/leukosis virus, and murine leukemia virus integration sites. Proc Natl Acad Sci U S A (2005) 2.64
Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis (2009) 2.60
Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA (2007) 2.59
Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (2004) 2.57
Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog (2010) 2.55
Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest (2011) 2.55
Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2010) 2.46
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44
IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest (2006) 2.41